Edition:
India

PerkinElmer Inc (PKI.N)

PKI.N on New York Stock Exchange

74.60USD
20 Apr 2018
Change (% chg)

$-0.50 (-0.67%)
Prev Close
$75.10
Open
$75.26
Day's High
$75.42
Day's Low
$74.29
Volume
167,583
Avg. Vol
190,849
52-wk High
$84.42
52-wk Low
$56.97

Latest Key Developments (Source: Significant Developments)

PerkinElmer Prices Offering Of Euro Denominated Senior Notes
Thursday, 5 Apr 2018 

April 4 (Reuters) - PerkinElmer Inc ::DENOMINATED SENIOR NOTES.HAS PRICED AN OFFERING OF EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF 0.600% SENIOR NOTES DUE 2021.  Full Article

Perkinelmer Inc Files Prospectus Supplement Related To A Potential Senior Notes Offering‍​
Wednesday, 4 Apr 2018 

April 4 (Reuters) - PerkinElmer Inc ::PERKINELMER INC FILES PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL SENIOR NOTES OFFERING - SEC FILING‍​‍​.  Full Article

RHS Enters Deal For Perkinelmer, Inc To Buy All Shares Of Co For $0.28 Per Share
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Rhs Ltd ::ENTERS SCHEME IMPLEMENTATION AGREEMENT FOR PERKINELMER, INC TO BUY ALL SHARES OF CO FOR $0.28 PER SHARE.CO'S BOARD UNANIMOUSLY RECOMMENDS THAT ALL RHS SHAREHOLDERS VOTE IN FAVOUR OF SCHEME.  Full Article

Perkinelmer Inc reports Q3 adjusted earnings per share $0.73
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Perkinelmer Inc :Perkinelmer Inc announces financial results for the third quarter of 2017.Q3 adjusted earnings per share $0.73.Q3 GAAP earnings per share $0.87 from continuing operations.Q3 revenue $554 million versus I/B/E/S view $552.5 million.Sees fy 2017 adjusted non-GAAP earnings per share $2.87 to $2.89.Sees fy 2017 GAAP earnings per share $2.55 to $2.57 from continuing operations.Q3 earnings per share view $0.72 -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $2.89 -- Thomson Reuters I/B/E/S.  Full Article

Phase II clinical trial data establishes effectiveness of child’s own cord blood treating cerebral palsy
Wednesday, 1 Nov 2017 

Oct 31 (Reuters) - Perkinelmer Inc :Phase II clinical trial data establishes effectiveness of using a child’s own cord blood to treat cerebral palsy.  Full Article

PerkinElmer ‍announced upcoming retirement of Andy Wilson CFO
Saturday, 16 Sep 2017 

Sept 15 (Reuters) - PerkinElmer Inc :PerkinElmer Inc - ‍Announced upcoming retirement of Andy Wilson, senior vice president and chief financial officer​.PerkinElmer Inc - ‍Wilson will retire in August 2018​.PerkinElmer Inc - ‍Company has engaged an executive recruiting firm to assist in an external search to fill CFO position​.  Full Article

Perkinelmer announces new organizational structure
Monday, 26 Sep 2016 

PerkinElmer Inc : PerkinElmer announces new organizational structure . Co's diagnostics business will become standalone business segment .Co's environmental health and life science solutions businesses will combine to form discovery & analytical solutions.  Full Article

Perkinelmer Inc entered into an unsecured revolving credit facility
Saturday, 13 Aug 2016 

Perkinelmer Inc : Perkinelmer inc says on august 11, 2016, entered into an unsecured revolving credit facility . Credit agreement replaces the unsecured revolving credit agreement dated as of january 8, 2014 - sec filing .Credit agreement provides for a $1 billion committed unsecured revolving credit facility through august 11, 2021.  Full Article

PerkinElmer Q2 adjusted earnings per share $0.67
Friday, 5 Aug 2016 

PerkinElmer Inc : Q2 GAAP earnings per share $0.56 from continuing operations . PerkinElmer Inc qtrly gaap earnings per share from continuing operations of $0.56 . Announces new eight million share repurchase authorization . Q2 adjusted earnings per share $0.67 . Q2 revenue $572.7 million versus $563.9 million . Reaffirms fy 2016 adjusted non-GAAP earnings per share view $2.75 to $2.85 . Reaffirms FY 2016 gaap earnings per share view $2.29 to $2.39 from continuing operations .Fy2016 earnings per share view $2.80, revenue view $2.32 billion -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-PerkinElmer Appoints James Mock As Chief Financial Officer

* PERKINELMER INC - ANDY WILSON WILL REMAIN WITH COMPANY AS AN ADVISOR FOR AN INTERIM PERIOD Source text for Eikon: Further company coverage: